According to a research report released Thursday, Citigroup has upgraded Merck MRK from Neutral to Buy, and increased PT from $34 to $50.
In the report, Citigroup said, "MRK announced that the Data Monitoring Committee (DMC) stopped its 16,500 patient Ph-III odanacatib (odana) trial early on a “favorable benefit-risk profile” in postmenopausal patients with osteoporosis. MRK expects to submit regulatory applications in the US/EU in 1H13 & Japan in 2H13."
Merck was trading up 4.34% from yesterday's $41.21 closing price.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in